Adeno-associated virus (AAV) forms the basis of one of the most promising and versatile vector systems for therapeutic human gene transfer. The genetic simplicity and low immunogenicity, paired with high plasticity and amenability to engineer and repurpose the viral capsid and genome, make it a popular choice for gene therapy. However, vectors based on natural versions of AAV face delivery barriers that limit their efficacy and will thus preclude the extension of these successes to many human diseases.
In this Cell & Gene Therapy Insights webinar, our distinguished guests, Dr. Dirk Grimm and Dr. David Schaffer will discuss the concept of using directed evolution to engineer highly optimized variants of AAV vectors. Our speakers will introduce key technologies for targeted modification and directed evolution of critical AAV components to address targeting, delivery, and potency barriers.
A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.
Attendees Will Discover Novel Approaches To:
- Leverage directed evolution strategies based on fundamentals of natural selection and survival of the fittest
- Configure viral vectors to mitigate toxicity from dosage and immunogenicity
- Select, create, and develop a top-performing AAV viral vector to enable gene therapy